Chemokine receptor antagonists and methods of use thereof
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
1. A pharmaceutical composition comprising an (S)-enantiomer compound, a physiologically acceptable carrier or excipient, and the (R)-enantiomer of said compound;
wherein the (S)-enantiomer compound has the formula:
or physiologically acceptable salt thereof, wherein
R 2 is 4-halophenyl; and
R 40 is selected from the group consisting of:
and
wherein the ratio of(S)-enantiomer to (R)-enantiomer (w/w)in said pharmaceutical composition is at least about 2:1.
2. The pharmaceutical composition of claim 1 , wherein the ratio of (S)-enantiomer to (R)-enantiomer (w/w) in said pharmaceutical composition is at least about 5:1.
3. The pharmaceutical composition of claim 1 , wherein the ratio of (S)-enantiomer to (R)-enantiomer (w/w) in said pharmaceutical composition is at least about 10:1.
4. The pharmaceutical composition of claim 1 , wherein the ratio of (S)-enantiomer to (R)-enantiomer (w/w) in said pharmaceutical composition is at least about 20:1.
5. The pharmaceutical composition of claim 1 , wherein the ratio of (S)-enantiomer to (R)-enantiomer (w/w) in said pharmaceutical composition is at least about 50:1.
6. A pharmaceutical composition comprising an (S)-enantiomer compound and a physiologically acceptable carrier or excipient: Wherein the (S)-enantiomer compound has the formula:
or physiologically acceptable salt thereof, wherein
R 2 is 4-halophenyl; and
R 40 is selected from the group consisting of:
and
wherein the pharmaceutical composition is substantially free of the (R)-enantiomer of said compound.